Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06625203 · ClinicalTrials.gov registry record
A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology
A clinical trial of Diffuse Large B Cell Lymphoma and Solid Tumor Cancer, sponsored by OWKIN.
- Recruiting
- Registry status
- 7,000
- Enrollment target
- 5
- Study locations
NCT06625203 is a study of Diffuse Large B Cell Lymphoma and Solid Tumor Cancer that is actively recruiting participants, run by OWKIN. The registered enrollment target is 7,000 participants, above the 157-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (4359% higher). The trial reports 5 study locations across 2 states.
The verdict
NCT06625203, a study of Diffuse Large B Cell Lymphoma and Solid Tumor Cancer, is actively recruiting participants, sponsored by OWKIN.
- RECRUITING
- Registry status
- 7,000 participants
- Enrollment target
- 5
- Study locations
Study Summary
Cancer is amongst the leading causes of disease-related morbidity and mortality. A major challenge in cancer treatment is the development of biology-informed, personalised treatment strategies. Recent advances in artificial intelligence (AI) and next-generation sequencing (NGS) technologies have shed further insights into disease biology and treatment pathways, thus identifying new, precision medicine-based therapeutic opportunities. The biological mechanisms leading to cancer development and progression arise from complex and plastic networks of dysregulated cellular programs involving many signalling pathways and effector molecules. Cancer cells alter their surrounding environment via cell-cell interactions with non-tumor cells or by secreting cytokines, chemokines and other factors. This reprogramming of the tumour microenvironment (TME) is critical for cancer progression, invasion, and metastasis. Moreover, there are increasing studies that show that both innate and adaptive immune cell types contribute to tumorigenesis and treatment resistance when present within the TME. Understanding the crosstalk between cancer cells and the surrounding TME will inform on mechanisms of sensitivity and resistance to treatment, including immunotherapy (IO) and targeted therapies. Spatially resolved-Omics is an emerging field that characterises cell types by gene/protein expressions within their spatial context in the tissue organisation. Recent high profile spatial transcriptomics studies have uncovered specific cell identities that define the surrounding TME. The MOSAIC study, a collaborative initiative across industry and top oncology hospitals, proposes to go way beyond current cancer molecular profiling projects by combining the generation and analysis of multiple data modalities (3 essential mandatory modalities: Clinical Data, Hematoxylin and Eosin (H\&E) microscopic image, Spatial transcriptomics; up to 3 high priority data modalities depending on technical feasibili
Conditions Studied
Study Locations (5)
Other
- Gustave Roussy - Paris
- Charité - Universitätsmedizin Berlin - Berlin
- Universiy Hospital Erlangen & FAU Erlangen-Nürnberg - Erlangen
- Centre Hospitalier Universitaire Vaudois - Lausanne
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,000 participants |
| Start Date | 2023-05-08 |
| Est. Completion | 2028-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06625203
The ClinicalTrials.gov registry entry for NCT06625203 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 7,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 157-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (4359% higher). The listed sponsor is OWKIN, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 0 interventions.
NCT06625203 reports 5 study locations spanning 2 distinct geographic areas - top geographies include Other, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06625203 about?
NCT06625203 is a clinical study titled "A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology". Cancer is amongst the leading causes of disease-related morbidity and mortality. A major challenge in cancer treatment is the development of biology-informed, personalised treatment strategies. Recent advances in artificial intelligence (AI) and next-generation sequencing (NGS) technologies have she...
What is the current status of trial NCT06625203?
This trial is currently recruiting. The enrollment target is 7,000 participants. The study started on 2023-05-08. Estimated completion is 2028-12.
What conditions does trial NCT06625203 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Solid Tumor Cancer.
Who is sponsoring clinical trial NCT06625203?
This trial is sponsored by OWKIN, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06625203 being conducted?
This trial has 5 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
RECRUITING · Phase 2
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.